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The signiﬁcance of patient and donor ethnicity on risk of acute graft-versus-host disease (GVHD) and
disease relapse after unrelated donor hematopoietic cell transplantation (HCT) is not known. A total of 4335
patientedonor pairs from the International Histocompatibility Working Group in HCT met the following 3
criteria: (1) HLA-A, -B, -C, -DRB1, and -DQB1 allele matched donor, (2) diagnosis of leukemia, and (3) noneT
cell depleted GVHD prophylaxis. Posttransplantation risks of acute GVHD and leukemia relapse were
deﬁned in Asian/Paciﬁc Islander, white, African American, Hispanic, and Native American patients that
underwent transplantation from donors with the same self-described background. Asian patients had
a signiﬁcantly lower incidence of acute GVHD (Japanese patients: 40.0% grades II to IV and 15.3% grades III to
IV; non-Japanese Asian patients: 42.1% grades II to IV and 15.7% grades III to IV) compared with white
patients (56.5% grades II to IV and 22.6% grades III to IV) (P < .001). The hazard ratio of acute GVHD for white
patients was signiﬁcantly higher than for Japanese patients. Unexpectedly, the hazard ratio of leukemia
relapse in white patients with early disease status was also signiﬁcantly higher than that in Japanese
patients. These results provide a platform for future investigation into the genetic factors for unrelated
donor HCT and clinical implications of diverse ethnic background.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION Clinical outcome after HCT depends on many factors
Patients who lack a matched sibling to serve as the
transplantation donor beneﬁt from hematopoietic cell
transplantation (HCT) from an HLAmatched unrelated donor
[1-6]. In both settings, donor recognition of recipient poly-
morphisms may lead to acute graft-versus-host disease
(GVHD), a potentially life-threatening complication that
necessitates long-term immunosuppressive therapy. HLA
identical siblings are identical by descent; hence, acute
GVHD arises from donor recognition of non-HLA poly-
morphisms located outside the HLA region [7]. Criteria for
unrelated donor selection is based on compatibility for
alleles of HLA-A, -C, -B, -DRB1, and -DQB1 genes because
matching is associated with lower risks of acute GVHD than
HLA mismatching. Acute GVHD after HLA matched unrelated
donor HCT may result from donor recognition of genome-
wide polymorphisms, including undetected variation
within the HLA region [8,9].edgments on page 1202.
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transplantation procedures used. In HLA matched sibling
transplantation, patient ethnicity has been reported to
inﬂuence the incidence of GVHD where white Americans,
African Americans, and Irish cohorts were at signiﬁcantly
higher risk for acute GVHD than were Japanese or Scandi-
navian cohorts [10]. The genetic basis that might explain
these different outcomes has not been deﬁned. The distri-
bution of HLA alleles is reﬂected in the ethnicity of the
population [11], and the probability of ﬁnding an HLA
matched unrelated donor is highest when the donor and
patient share the same ethnicity. The results of trans-
plantation from selected populations have been extensively
reported. In the US population of white patients receiving
a transplantation from a white unrelated donor [4], the
incidence of grades III to IV acute GVHD is 28% compared
with 11.8% observed in the Japanese experience [5]. These
data individually suggest that the risk of acute GVHD after
unrelated donor HCT depends on the patient’s and donor’s
ethnic backgrounds; however, a formal comparison of
outcomes among patients with different ethnic backgrounds
has never been undertaken. If the complications afterTransplantation.
Table 1
Characteristics of Hematopoietic Cell Transplantation from Unrelated Donors by Ethnicity
Total
Number
of Pairs
Ethnicity of PatienteDonor Pair
Japanese* Asian Excluding
Japanese
White African
American
Hispanic Native
American
Mismatched
Ethnicity
Unknown
Ethnicity
Number of pairs 4335 1734 19 1794 34 27 1 171 555
HLA-DPB1 matching
status (GVH
direction)
Match 1053 622 8 320 2 9 0 27 65
One allele mismatch 1530 798 3 553 12 3 0 45 116
Two allele mismatch 818 307 1 383 3 5 1 38 80
Unknown 934 7 7 538 17 10 0 61 294
Patient age, mean 33.8 30.4 33.9 36.5 34.1 30.4 d 35.3 35.4
Donor age, mean 34.7 34.3 35.4 35.1 38.9 34.0 d 35.1 34.6
Disease
ALL 1232 620 11 424 8 9 0 41 119
AML 1758 709 4 703 11 8 0 83 240
CML 1345 405 4 667 15 10 1 47 196
Disease risky
Low 938 273 3 480 5 7 1 29 140
Intermediate 2441 1093 10 910 19 16 0 94 299
High 931 352 6 399 10 4 0 46 114
Unknown 25 16 0 5 0 0 0 2 2
Patientedonor sex
Femaleemale 756 302 3 308 9 10 1 33 90
Maleefemale 944 341 6 435 5 4 0 45 108
Femaleefemale 811 335 3 324 9 3 0 39 98
Maleemale 1789 752 7 725 11 10 0 54 230
Unknown 35 4 0 2 0 0 0 0 29
GVHD prophylaxis
Cyclosporine based 2593 964 9 1167 19 12 1 97 324
Tacrolimus based 1536 757 10 592 15 14 0 70 78
Other 78 8 0 23 0 1 0 4 42
Unknown 128 5 0 12 0 0 0 0 111
Conditioning regimen
Myeloablative 3687 1631 18 1545 27 25 1 149 291
Nonmyeloablative/
reduced intensity
381 103 1 219 7 2 0 21 28
Unknown 267 0 0 30 0 0 0 1 236
Total body irradiation
No 949 315 1 423 10 5 0 44 151
Yes 3371 1419 18 1360 23 22 1 125 403
Unknown 15 0 0 1 1 0 0 2 1
Stem cell source
Bone marrow 3481 1734 9 1272 24 19 1 105 317
Peripheral blood
stem cells
854 0 10 522 10 8 0 66 238
Transplanted
yr (median)
d 1993-2005
(2000)
1991-2005
(2000)
1984-2007
(1999)
1991-2005
(2000)
1996-2006
(2001)
d d d
* Japanese include only individuals from the Japan Marrow Donor Program.
y Disease status before transplantation is categorized as low (CP of CML); intermediate (the ﬁrst or second CR of ALL, AML, or the second CP or accelerated
phase of CML); high risk (more advanced stage than intermediate risk).
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this information will facilitate future mapping of poly-
morphisms responsible for complications such as acute
GVHD and provide insight into the genetic basis of acute
GVHD. Furthermore, the information may have practical
value in the search for suitable unrelated donors.
We undertook a large-scale international study to deﬁne
risks after HLA matched unrelated donor HCT performed for
patients with different ethnic backgrounds within the
International Histocompatibility Working Group (IHWG) in
HCT [12]. These data provide a unique opportunity to eluci-
date the clinical effects of ethnicity on risk of acute GVHD
and leukemia relapse in HLA matched unrelated HCT.
METHODS
Study Population
A total of 4335 patients from the IHWG database met the following
criteria and were included in the current analysis: (1) transplantation from
an HLA-A, -B, -C, -DRB1, and -DQB1 allele compatible unrelated donor; (2)patient diagnosis of acute lymphoblastic leukemia (ALL), acute myeloid
leukemia (AML), or chronic myeloid leukemia (CML); and (3) noneT cell
depleted stem cell source without the use of antithymocyte globulin for
GVHD prophylaxis.
Patient characteristics by ethnicity are described in Table 1. Among these
subjects, 1232 patients carried the diagnosis of ALL, 1758 AML, and 1345
CML. Low-risk disease was deﬁned as a CML chronic phase (CP) at the time
of transplantation. The deﬁnition of disease risk was comparable among
clinical centers within IHWG. Intermediate risk was deﬁned as trans-
plantation in the ﬁrst or second complete remission (CR) of ALL, AML, or the
second CP or accelerated phase of CML. High risk was deﬁned as trans-
plantation in a more advanced stage than intermediate risk. Early status of
disease included patients in ﬁrst and second CR of ALL or AML at trans-
plantation or ﬁrst CP of CML at transplantation.
For GVHD prophylaxis, a tacrolimus-based regimen was used in 1536
patients, a cyclosporine-based regimen in 2593, and other regimens in 78.
Patients were conditioned for transplantation using either a myeloablative
(n ¼ 3687) or a nonmyeloablative/reduced-intensity regimen (n ¼ 381). A
total of 3481 patients was transplanted with bone marrow and 854 with
peripheral blood stem cells.
Informed consent was obtained from patients and donors in accordance
with the Declaration of Helsinki in each registry or institution, and consent
Figure 1. Cumulative incidence of acute GVHD by ethnicity. (A) Grades II to IV
acute GVHD; (B) grades III to IV acute GVHD. JJ, Japanese donor and patient
pair; CC, white donor and patient pair; AfAf, African American donor and
patient pair; HH, Hispanic donor and patient pair; API non-JJ, Asian/Paciﬁc
Islander donor and patients excluding Japanese pair; MM, mismatch race/
ethnicity pair between donor and patients. Incidence of acute GVHD is shown
in Supplemental Table S1.
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registry or institution before registration of the data or materials. Partici-
pating registries and institutions are listed in the Supplemental Table 6.DonoreRecipient Ethnicity
Patients were grouped as having the same, different, or unknown
ethnicity from their HLA matched unrelated donor according to self-
designated descriptions as deﬁned elsewhere [13]. A total of 3609 patients
had the same ethnicity as their donors (“matched ethnicity”); of these pairs,
1753 were of Asian/Paciﬁc Islander background (of which 1734 were
transplantations for Japanese pairs performed by the Japan Marrow Donor
Program in Japan), 1794 white, 34 African American, 27 Hispanic, and
1 Native American (Table 1). A total of 171 patients had a different back-
ground from their unrelated donor (“mismatched ethnicity”). Most pairs
with mismatched ethnicity (162 of 171) were of non-Asian backgrounds.
Ethnicity information of either patient or donor was not available for 555
pairs (“unknown ethnicity”).HLA Typing and HLA Matching
High-resolution HLA typing of patient and donor pairs was performed in
HLA typing laboratories or registries participating within the IHWG or in the
Division of Clinical Research of Fred Hutchinson Cancer Research Center as
described elsewhere [6,12]. HLA-DPB1 allele mismatching amongdonorerecipient pairs was scored when the recipients’ alleles were not
shared by the donor in GVH direction for all analyses.
Biostatistical Methods
Cumulative incidences of acute GVHD and relapse were assessed by
a method described elsewhere to eliminate the effect of competing risk [14].
Overall survival was calculated using the Kaplan-Meier method.
A competing event regarding acute GVHD was deﬁned as death without
acute GVHD, and a competing event regarding relapse was deﬁned as death
without relapse. A log-rank test was applied to assess the impact by the
factor of interest. Multivariable Cox regression analyses were conducted to
evaluate the impact of acute GVHD, leukemia relapse, and mortality after
transplantation. Confounders considered were combinations of ethnicity
between patient and donor, sex (donorerecipient pair), patient age (linear),
donor age (linear), risk of leukemia relapse (low, intermediate, and high),
GVHD prophylaxis (cyclosporine-based regimen, tacrolimus-based regimen,
and the other regimenwithout cyclosporine and tacrolimus), source of stem
cell, and preconditioning (myeloablative and nonmyeloablative/reduced
intensity). Missing events were treated as an unknown group.
RESULTS
Risk of Acute GVHD among Ethnicity Matched
DonoreRecipient Pairs
The cumulative incidence of acute GVHD in HLA-A, -B, -C,
-DRB1, and -DQB1 matched pairs was lower in patients of
Asian/Paciﬁc Islander background (Japanese pairs: 40.0%
grades II to IV and 15.3% grades III to IV; non-Japanese pairs:
42.1% grades II to IV and 15.7% grades III to IV) comparedwith
white background (56.5% grades II to IV and 22.6% grades III
to IV). The incidence of grades II to IV and III to IV acute GVHD
was 50.0% and 29.6% in African American pairs, 55.5% and
29.6% in Hispanic pairs, and 60.0% and 23.5% in patients of
mismatched ethnicity, respectively (Figure 1, Supplemental
Table S1).
Of the 4335 pairs, 1053 were matched for HLA-A, -B, -C,
-DRB1, -DQB1, and -DPB1 alleles (12/12 match). Japanese
pairs (n ¼ 622) showed a signiﬁcantly lower incidence of
acute GVHD than white pairs (n ¼ 320): 30.7% and 57.0% of
grades II to IV (P < .001) and 12.1% and 19.4% grades III to IV
(P ¼ .001), respectively.
Multivariate models adjusted for HLA-DPB1 match status
and clinical factors (see Methods) revealed that the hazard
ratio (HR) of acute GVHD in white pairs was signiﬁcantly
higher compared with Japanese pairs (reference group): HR
1.59 for grades II to IV (P < .001) and HR 1.48 for grades III to
IV (P < .001). The HR for acute GVHD in non-Japanese Asian
pairs was not signiﬁcantly higher compared with Japanese
pairs (reference group): HR 1.07 for grades II to IV (P ¼ .84)
and HR 1.03 for grades III to IV (P ¼ .96) (Table 2).
Risk of Leukemia Relapse among Ethnicity Matched
DonoreRecipient Pairs
Patients who experience acute GVHD may have a lower
risk of disease recurrence compared with patients without
GVHD, a phenomenon termed the graft-versus-leukemia
(GVL) effect.15 To better deﬁne GVHD-associated risks after
transplantation, we investigated the probability of disease
recurrence among the ethnicity-matched group. Using the
Japanese pairs as the reference, we unexpectedly found that
the HR for relapse in white patients was signiﬁcantly higher
compared with Japanese patients (HR 1.63, P < .001)
(Table 3). The rates of acute GVHD (grades II to IV and grades
III to IV) were not associated with differences in relapse rates
either in Japanese pairs or in white pairs (Supplemental
Table S2).
The cumulative incidence of relapse at 5 years after
transplantation was assessed according to myeloid or
lymphoid lineage of the leukemia and disease risk at the time
Table 2
HR of Acute GVHD, Leukemia Relapse, and Mortality by Ethnicity
N Grades II-IV Acute GVHD
HR (95% CI)
P Grades III-IV Acute GVHD
HR (95% CI)
P Relapse
HR (95% CI)
P Mortality
HR (95% CI)
P
Ethnicity
Japanese pair 1734 1.00 1.00 1.00 1.00
Asian pair excluding
Japanese
19 1.07 (.55-2.17) .84 1.03 (.32-3.23) .96 2.92 (1.59-5.36) .001 1.25 (.68-2.28) .46
White pair 1794 1.59 (1.42-1.77) <.001 1.48 (1.25-1.76) <.001 1.63 (1.40-1.90) <.001 1.46 (1.32-1.62) <.001
African pair 34 1.21 (.74-1.98) .43 1.81 (.94-3.45) .07 2.35 (1.24-4.47) .04 2.51 (1.67-3.76) <.001
Hispanic pair 27 1.61 (.96-2.64) .07 2.23 (1.09-4.53) .03 3.77 (2.00-7.13) <.001 2.87 (1.85-4.45) <.001
Mismatched race/ethnicity 171 1.71 (1.38-2.11) <.001 1.57 (1.12-2.22) .009 1.80 (1.34-2.42) <.001 1.62 (1.32-1.98) <.001
Unknown ethnicity 555 2.38 (2.01-2.83) <.001 1.48 (1.10-1.98) .008 1.56 (1.21-2.00) .005 1.33 (1.11-1.58) .001
HLA-DPB1 matching
(GVH direction)
Match 1053 1.00 1.00 1.00 1.00
One-allele mismatch 1530 1.34 (1.19-1.51) <.001 1.40 (1.15-1.69) .001 .66 (.57-.77) <.001 1.02 (.91-1.13) .69
Two-allele mismatch 818 1.48 (1.29-1.69) <.001 1.45 (1.16-1.80) <.001 .54 (.44-.66) <.001 1.01 (.89-1.15) .78
Unknown 934 1.20 (1.03-1.40) .01 1.12 (.87-1.43) .30 .62 (.51-.75) <.001 .74 (.64-.85) <.001
Multivariate analysis adjusted for clinical factors listed in Table 1. Data from 1 North American pair is not shown in this table.
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transplantation in early status of their disease (AML and ALL
in the ﬁrst CR or second CR, CML in the ﬁrst CP), white
patients had a signiﬁcantly higher relapse rate than Japanese
patients. In patients that underwent transplantation for
more advanced status of disease, relapse rates for white
patients and Japanese patients were not signiﬁcantly
different.
Risk of Survival among Ethnicity Matched
DonoreRecipient Pairs
Compared with Japanese patients, patients of white,
African American, or Hispanic backgrounds and patients who
received a transplantation from donors with a different
background had higher mortality, with the exception of non-
Japanese Asian patients (Table 2, Figure 2).
Factors Other than Ethnicity among Ethnicity Matched
DonoreRecipient Pairs
The increased HRs of acute GVHD and the decreased HRs
of relapse in 1 or 2 HLA-DPB1 mismatched transplantations
did not translate to any difference in survival by ethnicity
(Table 2). The HRs of the other factors for acute GVHD,
leukemia relapse, and mortality by multivariate analysis are
shown in Supplemental Table S3.
Because all Japanese patients received bone marrow for
the grafting source, the association of ethnicity with the HRs
of acute GVHD, leukemia relapse, and mortality for patientsTable 3
Leukemia Relapse Rate by Ethnicity, Leukemia Cell Type, and Status at
Transplantation
N ALL N AML N CML
Early status*
Japanese pair 469 23.9y 465 20.9 269 7.3
P ¼ .004 P < .001 P ¼ .02
White pair 298 30.5 436 30.7 478 10.7
Advanced statusz
Japanese pair 124 54.5 205 43.7 123 24.3
P ¼ .54 P ¼ .12 P ¼ .30
White pair 118 51.0 249 48.4 187 25.8
* First and second CR of ALL or AML at transplantation, ﬁrst CP of CML at
transplantation.
y Cumulative incidence (%) of leukemia relapse at 5 yrs after
transplantation.
z More advanced status than early status.receiving bone marrow transplantation are shown in
Supplemental Tables S4 and S5. The HRs of acute GVHD,
leukemia relapse, mortality, and relapse at 5 years after
transplantation between Japanese pairs and white pairsFigure 2. Survival after transplantation by ethnicity. (A) Patients with early
status of leukemia at transplantation; (B) patients with advanced status of
leukemia at transplantation. Early status: ﬁrst and second CR of ALL or AML at
transplantation, ﬁrst CP of CML. Advanced status: more advanced status than
early status. JJ, Japanese donor and patient pair; CC, white donor and patient
pair; AfAf, African American donor and patient pair; HH, Hispanic donor and
patient pair; API non-JJ, Asian/Paciﬁc Islander donor and patients excluding
Japanese pair; MM, mismatch ethnicity pair between donor and patients. Five-
year survival rate after transplantation by ethnicity is provided in
Supplemental Table S1.
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blood stem cell transplantation.
DISCUSSION
Donor HLA matching lowers risks of graft failure, acute
GVHD, morbidity, and mortality [2-6] and remains the
standard for the selection of unrelated donors for HCT.
Clinical experience demonstrates that the incidence of GVHD
after HLA matched unrelated HCT is not the same across
different populations [4,5]. The frequency of HLA phenotypes
and haplotypes differs worldwide [11,12], and information
regarding the content of HLA region variation is available for
selected populations [15,16]. We hypothesized that the risks
of GVHD depend on population-speciﬁc genetic variation.
We undertook the current analysis to compare the risks of
GVHD among patients of different ethnic backgrounds. This
information provides the necessary basis for future investi-
gation of the impact of speciﬁc genetic variation on clinical
outcome.
HLA antigens and haplotypes are population speciﬁc. The
IHWG database is a unique resource for the comparative
analysis of transplantation outcomes and HLA genetics. To
analyze acute GVHD and GVL effects clinically, it is essential
that nongenetic factors that also inﬂuence these
transplantation-related immunological events are taken
into consideration. Because HLA compatibility between the
patient and donor is a well-recognized risk factor for acute
GVHD and leukemia relapse in unrelated donor HCT
[1-6,17,18], we restricted the study population to HLA-A, -B,
-C, -DRB1, and -DQB1 allele matched pairs. GVHD prophy-
laxis is also another important factor for acute GVHD.
Therefore, only leukemia patients that underwent trans-
plantation from noneT cell depleted stem cell sources
without antithymocyte globulin were included in the anal-
ysis. White and Asian patients whose donors were also of
the same background were particularly well represented,
which permitted us to assess risks between these 2 pop-
ulations. A larger clinical experience will be needed to fully
evaluate clinical outcome in patients and donors of African
American, Hispanic, and Native American heritage.
This study shows that the incidence of acute GVHD in
Japanese patients is lower than that in white patients.
Although HLA-DPB1 mismatching is associated with risk of
acute GVHD [2,19], ethnicity was an independent risk factor
inHLA-A, -B, -C, -DRB1, and -DQB1matched transplantations;
furthermore, among pairs matched at all 6 classical loci,
including HLA-DPB1, we observed a signiﬁcantly higher
incidence of acute GVHD in white compared with Japanese
patients. Multi-single nucleotide polymorphism (SNP) anal-
ysis of the HLA region has been performed in Japanese [9,16]
and white [8] populations. We surmise that the lowered risk
of acute GVHD observed in the Japanese patients might be
explained in part by the high degree of conservation of the
HLA region for common HLA haplotypes in the Japanese
population, and/or the absence of GVHD risk determinants on
haplotypes in the Japanese population, and/or presence of
GVHD risk determinants on haplotypes inwhite populations.
Although our study population was matched for HLA, unre-
lated donors are only matched for HLA alleles; hence, HLA
matched pairs may have the same or different HLA haplo-
types, which could be a source of disparity for undetected
haplotype-linked variation [17].
In contrast to the homogeneity of the Japanese trans-
plantation population in which 3 extended HLA haplotypes
were observed at very high frequency [16], only 37 whitedonorerecipient pairs in the current study were homozy-
gous for the 4 most commonly observed white haplotypes.
Formal analysis of HLA haplotype-associated variation has
uncovered novel untyped variation responsible for GVHD in
white patients [18,19], and comparable analyses are
underway for Japanese pairs. Examination of MHC resident
variation should shed light on haplotype-linked poly-
morphisms unique to each ethnic group that could be
investigated in the future.
In the HLA region, several candidate genes exist in which
SNPs may be related to immune responses. Genetic variants
of TNF-a gene located in the HLA region might inﬂuence the
risk of developing GVHD [20-22]. In addition, TAP1/TAP2 and
LMP2/LMP7 genes encode subunit components of the pro-
teasome implicated in the processing of class I HLA-bound
peptides, and polymorphisms of these genes may affect
antigen presentation on recipient tissues, thus leading to
different susceptibility to GVHD.
In HCT from HLA-identical siblings, white Americans,
African Americans, and Irish cohorts were reported to be at
signiﬁcantly higher risk for acute GVHD than Japanese or
Scandinavian cohorts [10]. In unrelated donor HCT, there are
polymorphisms other than HLA. These data suggest that
other genetic differences might exist outside the HLA region.
Microbe-associated molecules [23], innate immune recep-
tors associated with GVHD, IL-10 [24], and heparanase [25]
are all candidates. The HLA alleles of each haplotype might
present different immunodominant peptides to T cells and
evoke different alloreactivity in HLA-matched unrelated
donor HCT [9]. The critical, but as yet unidentiﬁed, minor
histocompatibility antigens restricted by major histocom-
patibility antigens such as common gene deletion poly-
morphisms and the differences in ethnically diverse
populations should shed light [26]. Other intriguing candi-
date factors for acute GVHD might include environmental
factors, foods, and drug sensitivity of chemotherapeutic
regimens used speciﬁcally in transplantation and of other
pharmacological agents for health maintenance [27]. These
factors could be explored in unrelated as well as HCT from
HLA identical related donors.
In the current study, signiﬁcantly lower incidence of
relapse in Japanese pairs than that in white pairs was
observed in patients with early disease status. Japanese
patients had a lower relapse rate than white pairs regardless
of leukemia type and occurrence of acute GVHD. HLA-DPB1
mismatching was also an independent hazard risk for
leukemia relapse and lowered leukemia relapse in both
Japanese and white populations [28,29]. Although these
results might be induced in part by GVL effects, GVL effects
cannot entirely explain the difference of the risk of leukemia
relapse between the 2 ethnic populations. Although infor-
mation on pretransplantation induction/consolidation regi-
mens was not available, disease risk stage at the time of
transplantation is a surrogate for the risk of relapse. That
Japanese patients had both lower relapse and lower GVHD
risk compared with white patients suggests more complex
factors beyond the classic GVL effect, including GVHD-
dependent and GVHD-independent pathways. Yang et al.
[30] reported that leukemia relapse risk after chemotherapy
differed by ethnicity in children with ALL in a North Amer-
ican population, showing that Native Americans and
Hispanic ethnicity had a higher incidence of relapse rate. The
polymorphisms of chemotherapy resistance for relapse
speciﬁc to ethnicity might exist among ethnic groups. Iden-
tiﬁcation of non-HLA genes and alleles within the MHC and
Y. Morishima et al. / Biol Blood Marrow Transplant 19 (2013) 1197e12031202polymorphisms outside of the HLA region responsible for
leukemia relapse remains an important research goal.
Genome-wide analysis of world populations shows
intriguing genetic differences that are population-speciﬁc
[31]; however, genetics may be only 1 of several factors
that lead to differences in GVHD and mortality between
Japanese and white patients. The overwhelming majority of
Japanese patients included in this analysis were treated in
Japan and were therefore exposed to a relatively homoge-
neous “environment.” The impact of sociocultural and/or
dietary factors that could also inﬂuence posttransplantation
risks merits evaluation in future studies of ethnically diverse
populations, particularly transplantation outcomes for
patients of Japanese heritage who reside outside Japan.
Our study highlights the need for comprehensive analysis
of HLA region genetics as a starting point for identiﬁcation of
GVHD-associated polymorphisms. We used broad terms to
classify white, Hispanic, and African Americans; however,
each of these populations may include individuals of very
different ethnic backgrounds and is 1 limitation of our study
at present. Critical to achieving this goal is the need to deﬁne
the genetic diversity of all human populations given the
highly polymorphic nature of the HLA system. In the United
States, a larger clinical experience will aid our understanding
of the immunogenicity of speciﬁc HLA phenotypes repre-
senting African Americans, Hispanics, and Native Americans
[13,32]. Because most Asian/Paciﬁc Islander pairs in our
current study (1734 of 1753) were Japanese pairs registered
from the Japan Marrow Donor Program, the data are repre-
sentative of the Japanese population rather than Asian/
Paciﬁc ethnicities as a whole.
Contribution of data from other populations in the future
will aid in the effort to mapping transplantation determi-
nants, information that will beneﬁt all patients. The results of
our analysis provide a platform for future international
analyses of unrelated HCT outcomes and for international
exchange of unrelated donors.
ACKNOWLEDGMENTS
The authors thank all members of the IHWG hemato-
poietic cell transplantation component who contributed data
to this publication (Supplemental Table S6).
Financial disclosure: We are grateful for support from the
following agencies: Ministry of Health, Labor and Welfare,
Japan (grant H23-Immunology-010); Ministry of Education,
Culture, Sports, Science and Technology, Japan (grant 3224-
22133011); National Institutes of Health, Bethesda, Maryland
(grantsAI069197, CA100019, andCA18029 [to E.W.P. andM.M.]
and CA76518 to S.S.]); Health Resources and Services Admin-
istration, Rockville, Maryland, USA (HHSH234200637015C [to
S.S.]); and Ofﬁce of Naval Research, Arlington, Virginia, USA
(N00014-10-1-0204 and N00014-1-1-0339 [to S.S.]).
Authorship statement: Y.M., T.K., M.M., S.M., and E.W.P.
participated in the design and set up of this study. S.S., Y.M.,
K.K., S.K., M.M., E.W.P., A.C., J.T., D.S., A.V., and IHWG in HCT
participants (a complete list appears in Supplemental
Table S6) contributed to data collection and HLA typing.
T.K. performed the statistical analysis. Y.M., T.K., S.M., and
E.W.P. wrote the article.
SUPPLEMENTARY DATA
Supplementary data related to this article can be found
online at http://dx.doi.org/10.1016/j.bbmt.2013.05.020.REFERENCES
1. Petersdorf EW. Immunogenomics of unrelated hematopoietic cell
transplantation. Curr Opin Immunol. 2006;18:559-564.
2. Sasazuki T, Juji T, Morishima Y, et al. Effect of matching of class I HLA
alleles on clinical outcome after transplantation of hematopoietic stem
cells from an unrelated donor. Japan Marrow Donor Program. N Engl J
Med. 1998;339:1177-1185.
3. Petersdorf EW, Gooley TA, Anasetti C, et al. Optimizing outcome after
unrelated marrow transplantation by comprehensive matching of HLA
class I and II alleles in the donor and recipient. Blood. 1998;92:
3515-3520.
4. Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA
matching contributes to the success of unrelated donor marrow
transplantation. Blood. 2007;110:4576-4583.
5. Morishima Y, Sasazuki T, Inoko H, et al. The clinical signiﬁcance of
human leukocyte antigen (HLA) allele compatibility in patients
receiving a marrow transplant from serologically HLA-A, HLA-B, and
HLA-DR matched unrelated donors. Blood. 2002;99:4200-4206.
6. Spellman SR, Eapen M, Logan BR, et al. A perspective on the selection of
unrelated donors and cord blood units for transplantation. Blood. 2012;
120:259-265.
7. Goulmy E. Human minor histocompatibility antigens: new concepts for
marrow transplantation and adoptive immunotherapy. Immunol Rev.
1997;157:125-140.
8. Baschal EE, Aly TA, Jasinski JM, et al. Deﬁning multiple common
"completely" conserved major histocompatibility complex SNP haplo-
types. Clin Immunol. 2009;132:203-214.
9. Ogawa S, Matsubara A, Onizuka M, et al. Exploration of the genetic
basis of GVHD by genetic association studies. Biol Blood Marrow
Transplant. 2009;15(1 Suppl):39-41.
10. Oh H, Loberiza FR Jr, Zhang MJ, et al. Comparison of graft-versus-host-
disease and survival after HLA-identical sibling bone marrow trans-
plantation in ethnic populations. Blood. 2005;105:1408-1416.
11. Morishima Y, Kawase T, Malkki M, Petersdorf EW. Effect of HLA-A2
allele disparity on clinical outcome in hematopoietic cell trans-
plantation from unrelated donors. Tissue Antigens. 2007;69(Suppl 1):
31-35.
12. Petersdorf E, Bardy P, Cambon-Thomsen A, et al. 14th International
HLA and Immunogenetics Workshop: report on hematopoietic cell
transplantation. Tissue Antigens. 2007;69(Suppl 1):17-24.
13. Baker KS, Davies SM, Majhail NS, et al. Race and socioeconomic status
inﬂuence outcomes of unrelated donor hematopoietic cell trans-
plantation. Biol Blood Marrow Transplant. 2009;15:1543-1554.
14. Fine JP, Gray RJ. A proportional hazards model for the subdistribution
of a competing risk. J Am Stat Assoc. 1999;94:496-509.
15. Maiers M, Gragert L, Klitz W. High-resolution HLA alleles and haplo-
types in the United States population. Hum Immunol. 2007;68:779-788.
16. Morishima S, Ogawa S, Matsubara A, et al. Impact of highly conserved
HLA haplotype on acute graft-versus-host disease. Blood. 2010;115:
4664-4670.
17. Petersdorf EW, Malkki M, Gooley TA, et al. MHC haplotype matching
for unrelated hematopoietic cell transplantation. PLoS Med. 2007;4:e8.
18. Petersdorf EW, Malkki M, Gooley TA, et al. MHC-resident variation
affects risks after unrelated donor hematopoietic cell transplantation.
Sci Transl Med. 2012;4:144ra101.
19. Petersdorf EW, Malkki M, Horowitz MM, et al. Mapping MHC haplo-
type effects in unrelated donor hematopoietic cell transplantation.
Blood. 2013;121:1896-1905.
20. Hansen JA, Petersdorf EW, Lin MT, et al. Genetics of allogeneic hema-
topoietic cell transplantation. Role of HLA matching, functional varia-
tion in immune response genes. Immunol Res. 2008;41:56-78.
21. Bettens F, Passweg J, Schanz U, et al. Impact of HLA-DPB1 haplotypes
on outcome of 10/10 matched unrelated hematopoietic stem cell donor
transplants depends on MHC-linked microsatellite polymorphisms.
Biol Blood Marrow Transplant. 2012;18:608-616.
22. Harkensee C, Oka A, Onizuka M, et al. Single nucleotide polymorphisms
and outcome risk in unrelated mismatched hematopoietic stem cell
transplantation: an exploration study. Blood. 2012;119:6365-6372.
23. Penack O, Holler E, van den Brink MR. Graft-versus-host disease:
regulation by microbe-associated molecules and innate immune
receptors. Blood. 2010;115:1865-1872.
24. Lin MT, Storer B, Martin PJ, et al. Relation of an interleukin-10
promoter polymorphism to graft-versus-host disease and survival
after hematopoietic-cell transplantation. N Engl J Med. 2003;349:
2201-2210.
25. Ostrovsky O, Shimoni A, Rand A, et al. Genetic variations in the hep-
aranase gene (HPSE) associate with increased risk of GVHD following
allogeneic stem cell transplantation: effect of discrepancy between
recipients and donors. Blood. 2010;115:2319-2328.
26. Spierings E, Hendriks M, Absi L, et al. Phenotype frequencies of auto-
somal minor histocompatibility antigens display signiﬁcant differences
among populations. PLoS Genet. 2007;3:e103.
Y. Morishima et al. / Biol Blood Marrow Transplant 19 (2013) 1197e1203 120327. Rotta M, Storer BE, Storb RF, et al. Donor statin treatment protects
against severe acute graft-versus-host disease after related allogeneic
hematopoietic cell transplantation. Blood. 2010;115:1288-1295.
28. Kawase T, Matsuo K, Kashiwase K, et al. HLA mismatch combinations
associated with decreased risk of relapse: implications for the molec-
ular mechanism. Blood. 2009;113:2851-2858.
29. Fleischhauer K, Shaw BE, Gooley T, et al. Effect of T-cell-epitope
matching at HLA-DPB1 in recipients of unrelated-donor haemato-
poietic-cell transplantation: a retrospective study. Lancet Oncol. 2012;
13:366-374.30. Yang JJ, Chang C, Devidas M, et al. Ancestry and pharmacogenetics of
relapse in acute lymphoblastic leukemia. Nat Genet. 2011;43:
237-241.
31. 1000 Genomes Project Consortium, Abecasis GR, Altshuler D, et al.
A map of human genome variation from population-scale sequencing
[Erratum appears in Nature 2011 May 26;473(7348):544]. Nature.
2010;467:1061-1073.
32. Mielcarek M, Gooley T, Martin PJ, et al. Effects of race on survival after
stem cell transplantation. Biol Blood Marrow Transplant. 2005;11:
231-239.
